Sales & Marketing News | pharmaphorum

News

Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.

News

A survey has found that most patients with depression have little hope of being free of their symptoms, and Johnson & Johnson aims to change that.

News

Long-term third-party manufacturing contracts and a slower-than-expected rollout of its cancer ADCs have driven Daiichi Sankyo into a net loss.

News

Life sciences service provider EVERSANA has named industry veteran Mike Guarino to lead its global health agency EVERSANA INTOUCH.

News

Angelini has agreed to buy Catalyst Pharma for up to $4.1bn, its first acquisition since 2021, which would mark its entry into the US market.

News

Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.